Skip to main content

Antibe Therapeutics Inc(ATE-T)
TSX

Today's Change
Real-Time Last Update

Stocks in play: Antibe Therapeutics Inc.

Baystreet - Thu Sep 28, 2023

Announced Health Canada’s approval to initiate the pharmacokinetic/pharmacodynamic study of otenaproxesul’s faster-absorbing formulation for acute pain. Set to commence in October, the purpose of the study is to inform the doses for the Phase II trial. Antibe Therapeutics Inc. shares T.ATE are trading unchanged at $0.47.

Provided Content: Content provided by Baystreet. The Globe and Mail was not involved, and material was not reviewed prior to publication.

More from The Globe